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INTRODUCTION
Sinonasal malignancies involving the anterior skull base (ASB) are
challenging due to the complex anatomy and important structures
that may be involved (1). Many surgical techniques for approach-
ing this area have been developed for complete resection of these
tumors. Since Ketcham (2) first described the combined transcra-
nial and transfacial approach, the craniofacial resection has been
the standard surgical approach to sinonasal malignancies involv-
ing the anterior skull base. However, a new technique is needed
because of the high rate of surgical complications and morbidity
associated with the current approach (3, 4). In 1997, Yuen et al.
(5) first described an endoscopic technique for the resection of
an olfactory neuroblastoma (ONB) involving the ethmoid sinus
and cribriform plate. They used the term “cranionasal resection”
to distinguish it from a “craniofacial resection”. Since then, many
articles on endoscopic resection have been published internation-
ally (6-9). However, because of the rarity of sinonasal tumors
involving the anterior skull base, a long term follow-up study on
a large number of cases has not been carried out in Korea (10).
We retrospectively reviewed 46 patients diagnosed with sino-
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Original Articlenasal tumors. The clinical features were analyzed and the surgi-
cal complications and morbidity were compared according to the
surgical technique used, which included the traditional craniofacial
resection (TCFR) or the endoscopic craniofacial resection with
craniotomy (ECFR) (11).
MATERIALS AND METHODS
A retrospective chart review was performed on 46 patients who
were diagnosed with sinonasal tumors with involvement of the
ASB that underwent craniofacial resection between January 1989
through December 2006 at the Seoul National University Hospital
and Bundang Hospital. The patient records were reviewed for
demographic data, clinical presentation, operative procedures,
postoperative course, histopathological findings, immediate/
delayed complications, morbidity and mortality. Twenty-four
patients were male and 22 patients were female. The average age
of the patients was 43 yr, with a range of 5 to 70 yr. The mean
follow-up period was 31 months, with a range of 2 to 202 months.
The preoperative evaluation consisted of sinonasal endoscopy,
CT/MR scans and screening for distant metastasis: bone/liver scans
or positron emission tomography (PET). Patients who had re-
sectable lesions with no systemic metastasis underwent surgery.
Up until 1998, 18 cases of TCFR were performed; since 1999,
in cases without involvement of the orbit, skin or facial bones,
ECFR (10 cases) was performed; in patients with involvement,
TCFR (18 cases) was performed. In cases with malignant tumors,
ECFR was performed in 9 patients with ONB; for benign tumors,
ECFR was performed in 1 case with a meningioma. Our In-
stitutional Review Board approved the protocol for this retrospec-
tive analysis.
Endoscopic craniofacial resection with craniotomy
In all patients, CSF drainage was performed to minimize injury
to the frontal lobes during the retraction. For large tumors where
the origin could not be defined, the procedure began with mar-
gin clarification after tumor volume reduction with the use of a
microdebrider. The incision had a minimum margin of 1 cm from
the tumor attaching site. In cases where en bloc resection was
feasible, intranasal structures were included in the extent of the
resection after an accurate delineation of the tumor margin with
the use of an endoscope. A safe margin around the tumor was
ensured with a 1 cm incision. In the areas more apart from the
tumor margin a frozen section biopsy was done around the region
of the incision site. Then, subperiosteal dissection was performed
to identify the nasal septum, skull base and orbit. In areas such
as ethmoid sinus where the subperiosteal dissection was difficult,
the microdebrider was first used to reduce the mass volume and
then the mucosal dissection followed. For visualization, the sep-
tum was removed and the frontal or sphenoid sinus was opened.
An osteotomy was created at the lesion and the tumor was deliv-
ered through the craniotomy site. A pericranial flap was used for
reconstruction. No facial incision was made with this surgical tech-
nique in contrast to the TCFR.
Adjunctive treatment for ONB
Ten patients underwent TCFR, all were classified as Kadish type
C. Among them, eight patients had postoperative radiotherapy,
and chemotherapy was provided to one patient. In the nine patients
that had ECFR, six (Kadish type A: 1, B: 1, C: 4 cases) underwent
neoadjuvant chemotherapy and postoperative radiotherapy. Two
patients (Kadish type C) had postoperative radiotherapy only.
One patient with Kadish type C who showed partial remission
after neoadjuvant chemotherapy, was reluctant to receive surgery,
and had radiotherapy instead. However, there was no improve-
ment after the radiotherapy, and finally surgery with chemother-
apy was performed. The chemotherapy regimen consisted of
etoposide (75 mg/m
2/day, days 1-5), ifosfamide (1,000 mg/m
2/
day, days 1-5) and cisplatin (15 mg/m
2/day, days 1-5). At first,
two cycles of chemotherapy were administered and additional
cycles were planned according to the response to the first two
chemotherapy cycles. 
The initial symptoms, tumor involvement and the histopathol-
ogy were reviewed and the morbidity and complications were
assessed according to the surgical technique. The Mann-Whitney
U test and the Kaplan Meier method were used to identify the
surgical outcomes and morbidity of the patients receiving the TCFR
compared to those who had an ECFR. The data were analyzed
using SPSS 12.0 for Windows (SPSS Inc., Chicago, IL, USA). P-
values ≤0.05 were considered statistically significant.
RESULTS
Clinical features of the tumors
The patient presentation most commonly included a history of
nasal obstruction and unilateral epistaxis. The average duration
from symptom development to diagnosis was 4.3 months. The
sites commonly involved included the nasal cavity, ethmoid sinus
and cribriform plate. In addition, the sphenoid sinus, frontal lobe
Kim BJ et al.: Endoscopic Craniofacial Resection 149
Involved sites No.*
Table 1. Involved sites at diagnosis
Nasal cavity 27
Ethmoid sinus 23
Cribriform plate & frontal floor 23
Orbit 14
Maxillary sinus 11
Sphenoid sinus  11
Frontal sinus 5
Frontal lobe  4
Others (Masticator space, Cavernous sinus) 2
*The numbers are not mutually exclusive.and cavernous sinus were also involved (Table 1).
A list of the histopathological diagnoses is given in Table 2
and 3. The patients with benign tumors were followed with no
evidence of disease except one patient with a solitary fibrous
tumor that underwent malignant transformation (Table 3). For the
40 patients with a malignant tumor, 18 were followed with no
evidence of disease, and the survival outcomes depended on the
histopathological type of tumor (Table 4).
Treatment outcomes
Thirty-one patients out of 40 patients who were diagnosed with
malignant tumors, underwent a TCFR, of which 17 patients (55%)
developed disease recurrence; 11 had a local recurrence (35%),
4 had brain metastases (13%) and 2 had spinal metastases (6%).
One patient (11%) out of 9 who underwent an ECFR had a local
recurrence. For malignant tumors, the follow-up period ranged
from 2 to 116 months, with a mean of 25.4 months. The overall
5-yr survival rate for the sinonasal tumors involving the anteri-
or skull base was 47.4%.
Complications and morbidity
There were nine complications related to the surgery. Eight oc-
curred after the TCFR, and 1 case of an epidural hematoma occ-
urred after an ECFR. Complications related to the TCFR includ-
ed CSF leakage, meningitis, hematoma, and flap necrosis at the
facial incision site. Seven cases with complications were man-
aged by surgery such as a craniotomy and wound revision; one
patient expired due to complications and one patient had per-
sistent facial paralysis. Another two patients with complications
were treated with conservative antibiotic management. 
A subset of the patients who underwent an ECFR was select-
ed and compared to a group that underwent a TCFR. The groups
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Pathology TCFR ECFR Total
Table 2. Histopathologicical types of malignant tumors
TCFR: traditional craniofacial resection; ECFR: endoscopic craniofacial
resection with craniotomy.
Pathology Sex/age Involved sites Treatment F/U (mo) State
Table 3. Summary of benign tumors
N: nasal cavity; S: sphenoid sinus; M: maxillary sinus; O: orbit, E: ethomoid
sinus; C: cribriform plate & frontal floor; TCFR: traditional craniofacial resec-
tion; ECFR: endoscopic craniofacial resection with craniotomy; NED: no
evidence of disease; F/L: follow-up loss.
Olfactory neuroblastoma 10 9 19
Squamous cell carcinoma 7 7
Malignant melanoma 3 3
Rhabdomyosarcoma 2 2
Chondrosarcoma 2 2
Basal cell carcinoma 2 2
Undifferentiated carcinoma 1 1
Adenoid cystic carcinoma 1 1
Malignant meningioma 1 1
Undifferentiated sarcoma 1 1
Non-keratinizing carcinoma 1 1
Total 31 9 40
Pathology No. NED AWD DOD DOC F/L
Table 4. Follow-up of patients treated with craniofacial resection of
malignant tumors
NED: no evidence of disease; AWD: alive with disease; DOD: died of di-
sease; DOC: died from other causes; F/L: follow-up loss.
Angiofibroma M/16 N, middle TCFR 5 NED
cranial fossa
Angiofibroma M/16 S TCFR 72 NED
Angiofibroma M/13 N,S TCFR 95 NED
Ossifying M/16 E, S, cavernous TCFR 202 NED
fibroma sinus
Solitary fibrous M/38 N, M, O, E, C TCFR 29 F/L
tumor
Meningioma F/62 E, C ECFR 16 NED
Olfactory neuroblastoma  19 11 2 3 2 1
Squamous cell carcinoma 7 3 - 4 --
Malignant melanoma 3 -- 3 --
Rhabdomyosarcoma 2 1 1 ---
Chondrosarcoma 2 1 1 ---
Basal cell carcinoma 2 1 - 1 --
Undifferentiated carcinoma 1 ---- 1
Adenoid cystic carcinoma 1 - 1 ---
Malignant meningioma 1 ---- 1
Undifferentiated sarcoma 1 - 1 ---
Non-keratinizing carcinoma 1 1 ----
Total 40 18 6 10 2 4
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Fig. 1. Comparison in morbidity between surgical approaches using the Mann-Whitney U test. ECFR group shows shortened hospital stay and
operation time compared with TCFR group. ECFR: endoscopic craniofacial resection with craniotomy; TCFR: traditional craniofacial resection.Kim BJ et al.: Endoscopic Craniofacial Resection 151
were compared with respect to operation time, intraoperative
blood loss, length of hospital stay and length of ICU stay. The
ECFR group had a shortened length of stay and operation time;
these differences were statistically significant (P-value: 0.016 and
0.002 respectively). With respect to the length of the ICU stay
and the operation time, the differences did not reach statistical
significance (P-value: 0.679 and 0.059 respectively) (Fig. 1).
Postoperative course
In 19 patients with ONB, 10 patients underwent a TCFR, while
nine patients underwent an ECFR. For the patients with a TCFR,
the mean follow-up period was 28.8±34.7 months and six of
the 10 patients died of their disease (Table 5). For the patients
who had an ECFR, the mean follow-up period was 20.7±13.4
months and all nine patients are still alive (Table 6).
DISCUSSION
The incidence of sinonasal cancer has been reported to be one in
100,000 per year; it accounts for approximately 3% of all the
upper aerodigestive tract malignancies and less than 1% of all
cancers (12). In particular, the incidence of tumors involving the
anterior skull base is too low to analyze the demographic data
and survival outcome according to the histopathological type.
Squamous cell carcinomas and olfactory neuroblastomas are known
to be the two most common malignancies followed by primary
salivary gland tumors and sarcomas; our findings confirm this
(13). ONB is known to have a good prognosis. Although several
adjunctive treatments have been developed, surgery is considered
to be the standard treatment and postoperative radiotherapy is
recommended to improve the local control rate. The standard
treatment may vary according to the histopathological type of
tumor. However in many cases, there is no standard treatment
established to date.
Previously, craniofacial resections were associated with a high
rate morbidity and mortality related to the surgical technique (2,
14, 15). However, with progress in surgical methods and recon-
struction approaches such as the pericranial flap, the complica-
tion rate has decreased dramatically (16-18). Recently, nonin-
vasive surgical techniques have created a great deal of interest.
The endoscope assisted CFR has been developed and can be used
Sex/age Kadish stage Involved site Adjuvant Tx F/U (mo) State
Table 5. Olfactory neuroblastoma treated with TCFR (N=10)
N: nasal cavity; M: maxillary sinus; E: ethomoid sinus; C: cribriform plate & frontal floor; O: orbit; F: frontal sinus; S: sphenoid sinus; RT: radiotherapy; CTx:
chemotherapy; VIP: the VIP regimen consisted of vindesine (VDS 3 mg/m
2 on days 1 and 8), ifosfamide (IFX 1,300 mg/m
2 on days 1-5), and cisplatin (CDDP
20 mg/m
2 on days 1-5); CRT: chemoradiation; TCFR: traditional craniofacial resection; MRND: modified radical neck dissection; NED: no evidence of disease;
DOD: died of disease; DOC: died from other causes; AWD: alive with disease.
F/32 C N, M, E, C RT 22 NED
F/62 C N, E, O, F RT 5 DOD
M/60 C N, E, S RT  recurrence  CTx (VIP 3 cycles) 17 DOD
M/27 C N, Npx CTx (VIP 4  cycles) 56 NED
M/43 C M, E, S, C, O CRT  Recurrecne  Palliative CTx 20 DOD
M/35 C N, S, C, O RT 9.5 DOC
F/62 C N, C TCFR  Recurrence  Craniotomy 4 DOD
M/19 C N, E, O, C, Neck RT 3 DOD
F/19 C N, S, O RT 116 NED
F/47 C N, S, E, C RT  recurrence  MRND  recurrence  revion.maxillectomy 35 AWD
spinal metastasis
Sex/age Kadish Site Adjuvant treatment F/U (mo) State
Table 6. Olfactory neuroblastoma treated with ECFR (N=9)
ECFR: endoscopic craniofacial resection with craniotomy; N: nasal cavity;
E: ethomoid sinus; C: cribriform plate & frontal floor; S: sphenoid sinus; L:
frontal lobe; M: maxillary sinus; RT: radiotherapy; CTx: chemotherapy; VIP:
the VIP regimen consisted of vindesine (VDS 3 mg/m
2 on days 1 and 8),
ifosfamide (IFX 1,300 mg/m
2 on days 1-5), and cisplatin (CDDP 20 mg/m
2
on days 1-5); NED: no evidence of disease; AWD: alive with disease.
M/32 A N NeoCTx (VIP 2 cycles) 32 NED
postop RT
F/29 B N, E NeoCTx (VIP 1 cycle) 37 NED
postop RT
M/47 C N, E, C NeoCTx (VIP 2 cycles) 8 NED
postop RT
F/67 C N, E, C, S, L postop RT 4 NED
F/54 C N, C, S, M NeoCTx (VIP 4 cycles) 12 NED
postop RT
F/60 C N, L NeoCTx (VIP 2 cycles) 41 AWD
postop RT
F/64 C N, C, M, L NeoCTx (VIP 2 cycles) 15 NED
postop RT
M/40 C N, E, C NeoCTx (VIP 2 cycles) 25 NED
postop RT
F/36 C N, E, C NeoCTx (VIP 3 cycles) 13 NED
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clinically. Endoscopic surgery has been used in rhinosinusitis
surgery since the 1980s. As the knowledge and experience with
endoscopic surgery has improved, and the image guidance sys-
tems and surgical instruments for endoscopic surgery have evolved,
endoscopic surgery has been increasingly used for the treatment
of benign tumors (19). As experience with benign tumor surgery
accumulated, endoscopic surgery was adopted for the treatment
of malignant tumors (5-9, 20). Buchmann et al. (1) reported that
endoscopic instruments and techniques not only allowed excel-
lent visualization of the tumor, but also greatly aided the accu-
rate microscopic resection, resulting in good patient outcomes
and reduced surgery related morbidity. In 2006, Paolo et al. (8)
reported that the major exclusion criteria for an ECFR were as
follows: 1) tumors involving the lacrimal tract, 2) tumor infiltra-
tion of the hard palate, 3) tumors that involve the posterior
wall of the sphenoid sinus, and 4) tumor invasion of all but the
medial wall of the maxillary sinus. However, the indications for
an ECFR have not yet been established. The development of imag-
ing diagnostic tools as well as adjuvant treatments has expanded
the role of the ECFR. The development of imaging diagnostic
tools has enabled early detection and accurate preoperative eval-
uation. In addition, neoadjuvant/adjuvant chemotherapy and
radiotherapy has aided in improving treatment results (1, 21).
In our study, for the malignancies, ONB was the only histopatho-
logical type where the ECFR was used. This is due to the limita-
tions of the endoscopic approach and the advent of adjuvant ther-
apy for ONB. The endoscopic approach is limited in lesions involv-
ing the orbit, skin and facial bones. Consequently, an ONB, which
is commonly located at the interface between the superior nasal
cavity and the anterior cranial fossa, is a better indication for an
ECFR than squamous cell carcinoma, which commonly occurs
in the maxillary sinus and is invasive to adjacent structures. The
ONB originates from neuroendocrine cells similar to small cell
lung cancer, and small cell lung cancer is known to respond to
chemotherapy agents such as cisplatin. There is one report that
confirms that ONB is responsive to cisplatin (22). Therefore, at
our institution, a combined modality treatment has been adopt-
ed, in which initial cisplatin based neoadjuvant chemotherapy
(VIP) is provided to reduce the tumor volume and surgery is pl-
anned to minimize the functional and cosmetic deformities. In
addition, in patients with Kadish type C disease, postoperative
radiotherapy is recommended (21, 23, 24). The development of
adjuvant therapy has supplemented the limitations of endoscop-
ic resection and allows for a more expanded use of endoscopy
with other histopathological tumor types.
The results of this study showed that the patients who had an
ECFR had a tendency to have reduced morbidity and a good
survival outcome. However, in most ECFR cases, neoadjuvant
chemotherapy and postoperative radiotherapy were performed,
and the follow-up period was relatively short, in contrast to the
TCFR cases, where neoadjuvant chemotherapy was not usually
performed. Therefore, further long term follow-up studies are
needed to evaluate the outcomes of the ECFR compared to the
TCFR with respect to oncological safety and survival.
In conclusion, the ECFR may have the advantages of reducing
the surgery related morbidity and mortality compared to the TCFR.
Therefore, it should be considered as an alternative treatment
option for selected sinonasal tumors involving anterior skull base.
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